Literature DB >> 1099147

Susceptibility of coccidioides immitis, Candida albicans, and Cryptococcus neoformans to amphotericin B, flucytosine, and clotrimazole.

P D Hoeprich, A C Huston.   

Abstract

Toxicity and failure of treatment with amphotericin B are stimuli for researchers to evaluate alternative antifungal antimicrobics. Also, data from susceptibility tests of Coccidioides immitis are sparse. With use of a defined, synthetic culture medium, C. immitis (25 strains). Candida albicans (21 strains), and Cryptococcus neoformans (21 strains) were tested against flucytosine, clotrimazole, and amphotericin B. Molecule for molecule, the sequency of activity was: clotrimazole greater than amphotericin B greater than flucytosine (totally inactive) C. immitis; and clotrimazole greater than amphotericin B greater than flucytosine with C. albicans and C. neoformans. With four strains of C. immitis, the minimal inhibitory concentration (of amphotericin B) was the same when inocula of arthrospores were tested as when corresponding spherules/endospores were tested simultaneously and identically. The clinical outcome of coccidioidomycosis in 17 patients treated with amphotericin B correlated best with minimal inhibitory concentration after incubation of cultures for 48 hr; a favorable response was associated with minimal inhibitory concentrations of less than or equal 1.0 mug/ml. Because clinical isolates of fungi appear to vary in susceptibility, in vitro tests may have clinical utility.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1099147     DOI: 10.1093/infdis/132.2.133

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Uniform susceptibility of various strains of Coccidioides immitis to amphotericin B.

Authors:  M S Collins; D Pappagianis
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

2.  Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: in vitro and clinical correlations.

Authors:  R Pelletier; J Peter; C Antin; C Gonzalez; L Wood; T J Walsh
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

3.  Entry of five antifungal agents into the ovine lung.

Authors:  P D Hoeprich; J M Merry; R Gunther; C E Franti
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

4.  Microtiter method for MIC testing with spherule-endospore-phase Coccidioides immitis.

Authors:  R F Hector; B L Zimmer; D Pappagianis
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

5.  Modulation of macrophage tumoricidal capability by polyene antibiotics: support for membrane lipid as a regulatory determinant of macrophage function.

Authors:  H A Chapman; J B Hibbs
Journal:  Proc Natl Acad Sci U S A       Date:  1978-09       Impact factor: 11.205

6.  Inhibition of potentially pathogenic yeastlike fungi by clotrimazole in combination with 5-fluorocytosine or amphotericin B.

Authors:  W H Beggs; G A Sarosi; N M Steele
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

7.  Comparative susceptibility of four kinds of pathogenic fungi to amphotericin B and amphotericin B methyl ester.

Authors:  A C Huston; P D Hoeprich
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

8.  Rapid microdilution-colorimetric assay for yeast susceptibility to fluorocytosine.

Authors:  B D Fisher; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1977-11       Impact factor: 5.191

9.  Comparative pharmacology of amphotericin B and amphotericin B methyl ester in the non-human primate, Macacca mulatta.

Authors:  F A Jagdis; P D Hoeprich; R M Lawrence; C P Schaffner
Journal:  Antimicrob Agents Chemother       Date:  1977-11       Impact factor: 5.191

10.  Disk agar diffusion susceptibility testing of yeasts.

Authors:  M A Saubolle; P D Hoeprich
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.